5 news items
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FGEN
23 May 24
of the trial and further explore the potential of 89Zr-DFO-YS5 as a predictive biomarker of response." The poster
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
evaluable patients, 20% met the criteria of a partial response, or measurable tumor reduction in size of ≥ 30%, with a median duration of response
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
ABBV
FGEN
3 Apr 24
evaluable patients.
20% met the criteria of a partial response, or tumor reduction in size of over 30%, with a median duration of response
FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246
FGEN
2 Apr 24
patients, 20% met the criteria of a partial response, or tumor reduction in size of ≥ 30%, with a median duration of response of 7.5
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
PSA50 response in 36% of patients
- Prev
- 1
- Next